• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Radiotherapy holds lung tumors at three years

Article

Highly focused stereotactic body radiation therapy can eliminate tumors better than conventional radiotherapy and may improve survival for inoperable non-small cell lung cancer, according to a Radiation Therapy Oncology Group study.

Highly focused stereotactic body radiation therapy can eliminate tumors better than conventional radiotherapy and may improve survival for inoperable non-small cell lung cancer, according to a Radiation Therapy Oncology Group study.

The most exciting aspect of the prospective study was the high rate of primary tumor control-97.6%-at three years, according to Dr. Robert Timmerman, a professor at the University of Texas Southwestern Medical Center in Dallas and principal investigator of the study.

Stereotactic body radiation therapy as delivered in the trial more than doubled the rate of primary tumor control provided by conventional radiotherapy, he said. This suggests the technique could provide a significant step forward in the battle against inoperable non-small cell lung cancer.

The phase II study included 59 patients with biopsy-proven peripheral non-small cell tumors measuring less than 5 cm in diameter with conditions disallowing surgical treatment.

This was the first North American multicenter cooperative group study to test stereotactic body radiation therapy in treating these types of patients. It was published in the March 17 Journal of the American Medical Association.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.